vs
美泰（MAT）与百利高（PRGO）财务数据对比。点击上方公司名可切换其他公司
百利高的季度营收约是美泰的1.3倍（$1.1B vs $862.2M），美泰净利率更高（7.1% vs -127.8%，领先134.9%），美泰同比增速更快（4.3% vs -2.5%），百利高自由现金流更多（$148.6M vs $-88.1M），过去两年百利高的营收复合增速更高（1.3% vs -10.6%）
美泰是美国知名玩具及娱乐企业，旗下影视制作部门美泰影业运营时间为2018年9月6日至2025年6月2日。其前身为2013年10月16日成立的美泰Playground Productions，更早可追溯至美泰娱乐、美泰工作室等集团原有娱乐业务品牌。
百利高（Perrigo）是一家注册于爱尔兰的非处方仿制药生产商，主打自有品牌OTC药品业务。公司70%的净销售额来自美国医疗市场，为优化税务布局将法定总部设在爱尔兰，该地区销售额仅占总营收的0.6%，2013年曾完成美国历史上第六大企业税收倒置交易。
MAT vs PRGO — 直观对比
营收规模更大
PRGO
是对方的1.3倍
$862.2M
营收增速更快
MAT
高出6.8%
-2.5%
净利率更高
MAT
高出134.9%
-127.8%
自由现金流更多
PRGO
多$236.7M
$-88.1M
两年增速更快
PRGO
近两年复合增速
-10.6%
损益表 — Q1 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $862.2M | $1.1B |
| 净利润 | $61.0M | $-1.4B |
| 毛利率 | 44.9% | 32.6% |
| 营业利润率 | — | -116.0% |
| 净利率 | 7.1% | -127.8% |
| 营收同比 | 4.3% | -2.5% |
| 净利润同比 | 251.4% | -3093.9% |
| 每股收益（稀释后） | $0.20 | $-10.23 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收MATPRGO
| Q1 26 | $862.2M | — | ||
| Q4 25 | $1.8B | $1.1B | ||
| Q3 25 | $1.7B | $1.0B | ||
| Q2 25 | $1.0B | $1.1B | ||
| Q1 25 | $826.6M | $1.0B | ||
| Q4 24 | $1.6B | $1.1B | ||
| Q3 24 | $1.8B | $1.1B | ||
| Q2 24 | $1.1B | $1.1B |
净利润MATPRGO
| Q1 26 | $61.0M | — | ||
| Q4 25 | $106.2M | $-1.4B | ||
| Q3 25 | $278.4M | $7.5M | ||
| Q2 25 | $53.4M | $-8.4M | ||
| Q1 25 | $-40.3M | $-6.4M | ||
| Q4 24 | $140.9M | $-44.4M | ||
| Q3 24 | $372.4M | $-21.0M | ||
| Q2 24 | $56.9M | $-108.4M |
毛利率MATPRGO
| Q1 26 | 44.9% | — | ||
| Q4 25 | 45.9% | 32.6% | ||
| Q3 25 | 50.0% | 36.1% | ||
| Q2 25 | 50.9% | 34.4% | ||
| Q1 25 | 49.4% | 37.6% | ||
| Q4 24 | 50.7% | 33.9% | ||
| Q3 24 | 53.1% | 37.2% | ||
| Q2 24 | 49.2% | 37.0% |
营业利润率MATPRGO
| Q1 26 | — | — | ||
| Q4 25 | 8.0% | -116.0% | ||
| Q3 25 | 21.9% | 7.0% | ||
| Q2 25 | 7.7% | 4.3% | ||
| Q1 25 | -6.4% | 4.5% | ||
| Q4 24 | 9.6% | 10.0% | ||
| Q3 24 | 26.5% | 7.4% | ||
| Q2 24 | 7.7% | -2.5% |
净利率MATPRGO
| Q1 26 | 7.1% | — | ||
| Q4 25 | 6.0% | -127.8% | ||
| Q3 25 | 16.0% | 0.7% | ||
| Q2 25 | 5.2% | -0.8% | ||
| Q1 25 | -4.9% | -0.6% | ||
| Q4 24 | 8.6% | -3.9% | ||
| Q3 24 | 20.2% | -1.9% | ||
| Q2 24 | 5.3% | -10.2% |
每股收益（稀释后）MATPRGO
| Q1 26 | $0.20 | — | ||
| Q4 25 | $0.32 | $-10.23 | ||
| Q3 25 | $0.88 | $0.05 | ||
| Q2 25 | $0.16 | $-0.06 | ||
| Q1 25 | $-0.12 | $-0.05 | ||
| Q4 24 | $0.40 | $-0.32 | ||
| Q3 24 | $1.09 | $-0.15 | ||
| Q2 24 | $0.17 | $-0.79 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $866.0M | — |
| 总债务越低越好 | $2.3B | — |
| 股东权益账面价值 | $2.1B | $2.9B |
| 总资产 | $6.3B | $8.5B |
| 负债/权益比越低杠杆越低 | 1.11× | — |
8季度趋势，按日历期对齐
现金及短期投资MATPRGO
| Q1 26 | $866.0M | — | ||
| Q4 25 | $1.2B | — | ||
| Q3 25 | $691.9M | $432.1M | ||
| Q2 25 | $870.5M | $454.2M | ||
| Q1 25 | $1.2B | $409.9M | ||
| Q4 24 | $1.4B | $558.8M | ||
| Q3 24 | $723.5M | $1.5B | ||
| Q2 24 | $722.4M | $542.8M |
总债务MATPRGO
| Q1 26 | $2.3B | — | ||
| Q4 25 | $2.3B | — | ||
| Q3 25 | $2.3B | — | ||
| Q2 25 | $2.3B | — | ||
| Q1 25 | $2.3B | — | ||
| Q4 24 | $2.3B | — | ||
| Q3 24 | $2.3B | — | ||
| Q2 24 | $2.3B | — |
股东权益MATPRGO
| Q1 26 | $2.1B | — | ||
| Q4 25 | $2.2B | $2.9B | ||
| Q3 25 | $2.3B | $4.4B | ||
| Q2 25 | $2.2B | $4.5B | ||
| Q1 25 | $2.1B | $4.4B | ||
| Q4 24 | $2.3B | $4.3B | ||
| Q3 24 | $2.3B | $4.6B | ||
| Q2 24 | $2.0B | $4.5B |
总资产MATPRGO
| Q1 26 | $6.3B | — | ||
| Q4 25 | $6.6B | $8.5B | ||
| Q3 25 | $6.6B | $10.1B | ||
| Q2 25 | $6.2B | $10.1B | ||
| Q1 25 | $6.2B | $9.8B | ||
| Q4 24 | $6.5B | $9.6B | ||
| Q3 24 | $6.5B | $11.2B | ||
| Q2 24 | $5.9B | $10.4B |
负债/权益比MATPRGO
| Q1 26 | 1.11× | — | ||
| Q4 25 | 1.04× | — | ||
| Q3 25 | 1.03× | — | ||
| Q2 25 | 1.08× | — | ||
| Q1 25 | 1.10× | — | ||
| Q4 24 | 1.03× | — | ||
| Q3 24 | 1.01× | — | ||
| Q2 24 | 1.18× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | — | $175.4M |
| 自由现金流经营现金流 - 资本支出 | $-88.1M | $148.6M |
| 自由现金流率自由现金流/营收 | -10.2% | 13.4% |
| 资本支出强度资本支出/营收 | 7.6% | 2.4% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | — | $145.1M |
8季度趋势，按日历期对齐
经营现金流MATPRGO
| Q1 26 | — | — | ||
| Q4 25 | $796.6M | $175.4M | ||
| Q3 25 | $72.0M | $51.7M | ||
| Q2 25 | $-300.1M | $75.9M | ||
| Q1 25 | $24.8M | $-64.5M | ||
| Q4 24 | $862.1M | $312.6M | ||
| Q3 24 | $155.8M | $42.2M | ||
| Q2 24 | $-252.9M | $9.5M |
自由现金流MATPRGO
| Q1 26 | $-88.1M | — | ||
| Q4 25 | — | $148.6M | ||
| Q3 25 | — | $29.8M | ||
| Q2 25 | — | $56.7M | ||
| Q1 25 | — | $-90.0M | ||
| Q4 24 | — | $274.9M | ||
| Q3 24 | — | $15.1M | ||
| Q2 24 | — | $-18.9M |
自由现金流率MATPRGO
| Q1 26 | -10.2% | — | ||
| Q4 25 | — | 13.4% | ||
| Q3 25 | — | 2.9% | ||
| Q2 25 | — | 5.4% | ||
| Q1 25 | — | -8.6% | ||
| Q4 24 | — | 24.2% | ||
| Q3 24 | — | 1.4% | ||
| Q2 24 | — | -1.8% |
资本支出强度MATPRGO
| Q1 26 | 7.6% | — | ||
| Q4 25 | — | 2.4% | ||
| Q3 25 | — | 2.1% | ||
| Q2 25 | — | 1.8% | ||
| Q1 25 | — | 2.4% | ||
| Q4 24 | — | 3.3% | ||
| Q3 24 | — | 2.5% | ||
| Q2 24 | — | 2.7% |
现金转化率MATPRGO
| Q1 26 | — | — | ||
| Q4 25 | 7.50× | — | ||
| Q3 25 | 0.26× | 6.89× | ||
| Q2 25 | -5.62× | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 6.12× | — | ||
| Q3 24 | 0.42× | — | ||
| Q2 24 | -4.45× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
MAT
暂无分部数据
PRGO
| Consumer Self Care Americas | $697.0M | 63% |
| Digestive Health | $123.9M | 11% |
| Nutrition | $108.3M | 10% |
| Healthy Lifestyle | $94.8M | 9% |
| Pain And Sleep Aids | $87.1M | 8% |
